Assura plc

Development Update

RNS Number : 8649G
Assura PLC
01 April 2022
 

1 April 2022

Assura plc

Development update

Assura plc ("Assura"), the leading primary care property investor and developer, today announces it has reached financial close on a development funding agreement for a £31 million cancer diagnostic and treatment centre in Guildford.

The building will be operated by and let to Genesis Cancer Care UK Limited ("GenesisCare") on a 30-year FRI lease with annual, index-linked rent reviews.

The building, situated adjacent to the Royal Surrey County Hospital, will provide cutting-edge oncology and cancer care services via a partnership agreement between GenesisCare and the Royal Surrey NHS Foundation Trust. The cancer centre will house two radiotherapy treatment bunkers (one state-of-the-art MR-guided Linac and one conventional Linac) as well as diagnostic facilities and a radiopharmacy facility for the provision of nuclear medicine imaging and treatment.

The building is expected to achieve a BREEAM rating of Very Good, with Excellent for the Energy component, and an EPC of A. The building will include PV panels, LED lighting throughout and EV charging points. The site will benefit from creation of a new sensory garden for patient and staff wellbeing and we have also introduced an education and skills bursary package as part of our overall funding approach.

The centre is being developed by Prime and built by Vinci Construction, with practical completion expected by Q4 2023.

Jonathan Murphy, CEO, said:

"We are pleased to be working with Prime again to forward fund this scheme in Guildford. This new, state-of-the-art facility will deliver services that ease the burden on the local NHS and help create additional capacity within existing NHS assets to address treatment backlogs.

"This scheme is another step on our strategy to expand our offering, working with selected high-quality private providers who partner with the NHS as well as having a high sustainability and social impact."

- ENDS -

 

For more information, please contact:

Assura plc

David Purcell, Head of Investor Relations

Tel: 01925 945354

Email: [email protected]

Finsbury

Gordon Simpson
James Thompson

Tel: 0207 251 3801

Email: [email protected]

 

Notes to Editors

Assura plc, a constituent of the FTSE 250 and the EPRA* indices, is a UK REIT and long-term investor in and developer of primary care property. The company, headquartered in Warrington, works with GPs, health professionals and the NHS to create outstanding spaces for health services in our communities. At 30 September 2021, Assura's property portfolio was valued at £2,595 million.

 

 

Further information is available at www.assuraplc.com

 

*EPRA is a registered trademark of the European Public Real Estate Association.

 

Assura plc LEI code: 21380026T19N2Y52XF72

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTWPUPWWUPPPUG